STOK Stoke Therapeutics Q4 2025 EPS misses estimates by 333 pushing shares 258 lower in todays session BCARW BoralARCWrt key quarterly earnings metrics remain undisclosed as the firm finalizes formal financial reporting What idiosyncratic risk Dolphin Ent DLPN Market Focus 20260427 NetEase Inc NTES Files Fiscal 2025 Annual Report on Form 20F Opens Hard Copy Access for Shareholders FORA Forian posts steep Q4 2025 EPS shortfall yet stock notches small gains following earnings release Summit Therapeutics SMMT Stock Is It the Right Time to Invest Q4 2025 Below Expectations